Fig. 3—
Cumulative survival of patients with fenfluramineassociated pulmonary arterial hypertension (fenPAH; ·····) and idiopathic and familial (I/P PAH; ——). At 0, 24, 48, 72, 96, 120, 144, 168, 192, 216 and 240 months, the number of patients in the I/FPAH group was 496, 298, 163, 104, 57, 24, 13, 6, 4, 3 and 2, respectively, while in the fenPAH group, it was 109, 64, 40, 26, 17, 10, 6, 4, 2, 1 and 0. #: p=0.3, logrank.